Director Shareholding and Other Holdings

RNS Number : 0658K
Instem plc
23 December 2015
 

 

 

Instem plc
("Instem" or the "Company")

 

Director Shareholding and Other Holdings in the Company

 

Instem (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, was notified today of the following deals in the ordinary shares of 10 pence each in the Company ("Ordinary Shares") by David Gare, Chairman. 

 

David Gare is a trustee of the 'The DG 2008 Discretionary Settlement' (the "Trust") which on 23rd December 2015 transferred 80,000 Ordinary Shares to each of two beneficiaries, Michael Adrian Gare and Deborah Jane Walker, at a price of two hundred and thirty pence per Ordinary Share (the "Transaction").

 

Following the Transaction, the notifiable interests of the above parties are as follows:

 

 

Number of Ordinary Shares Held

Percentage of Total Ordinary Shares

David Gare, Chairman*

2,118,427

16.2%

Michael Adrian Gare

784,219

6.0%

Deborah Jane Walker

784,219

6.0%

 

*Note: these 2,118,427 Ordinary Shares are held by the Trust.

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000             

Richard Lindley

 

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

 

 

About Instem plc

 

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, the United Kingdom, India and China, with additional presence in France and Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSTJBJTMBBTBIA

Companies

Instem (INS)
UK 100